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Abstract
Introduction In breast cancer, deregulation of the WNT
signaling pathway occurs by autocrine mechanisms. WNT
ligands and Frizzled receptors are coexpressed in primary breast
tumors and cancer cell lines. Moreover, many breast tumors
show hypermethylation of the secreted Frizzled-related protein 1
(sFRP1) promoter region, causing low expression of this WNT
antagonist. We have previously shown that the WNT pathway
influences proliferation of breast cancer cell lines via activation
of canonical signaling and epidermal growth factor receptor
transactivation, and that interference with WNT signaling
reduces proliferation. Here we examine the role of WNT
signaling in breast tumor cell migration and on xenograft
outgrowth.
Methods The breast cancer cell line MDA-MB-231 was used to
study WNT signaling. We examined the effects of activating or
blocking the WNT pathway on cell motility by treatment with
WNT ligands or by ectopic sFPR1 expression, respectively. The
ability of sFRP1-expressing MDA-MB-231 cells to grow as
xenografts was also tested. Microarray analyses were carried
out to identify targets with roles in MDA-MB-231/sFRP1 tumor
growth inhibition.
Results We show that WNT stimulates the migratory ability of
MDA-MB-231 cells. Furthermore, ectopic expression of sFRP1
in MDA-MB-231 cells blocks canonical WNT signaling and
decreases their migratory potential. Moreover, the ability of
MDA-MB-231/sFRP1-expressing cells to grow as xenografts in
mammary glands and to form lung metastases is dramatically
impaired. Microarray analyses led to the identification of two
genes, CCND1 and CDKN1A, whose expression level is
selectively altered in vivo in sFRP1-expressing tumors. The
encoded proteins cyclin D1 and p21Cip1 were downregulated
and upregulated, respectively, in sFRP1-expressing tumors,
suggesting that they are downstream mediators of WNT
signaling.
Conclusions Our results show that the WNT pathway
influences multiple biological properties of MDA-MB-231 breast
cancer cells. WNT stimulates tumor cell motility; conversely
sFRP1-mediated WNT pathway blockade reduces motility.
Moreover, ectopic sFRP1 expression in MDA-MB-231 cells has
a strong negative impact on tumor outgrowth and blocked lung
metastases. These results suggest that interference with WNT
signaling using sFRP1 to block the ligand- receptor interaction
may be a valid therapeutic approach in breast cancer.
Introduction
The WNT signaling network is complex, with 19 WNT ligands,
10 Frizzled (FZD) receptors, as well as the co-receptors, low-
density lipoprotein receptor-related protein (LRP) 5 and LRP6.
WNT receptor binding stimulates intracellular signaling, pro-
moting stabilization and nuclear translocation of the key effec-
tor of the canonical pathway, β-catenin [1,2]. Intracellular
mediators of the WNT pathway are mutated in many human
cancers. Inactivating mutations in the APC or AXIN genes, as
well as activating CTNNB1 mutations, each causes β-catenin
stabilization and nuclear accumulation in the absence of WNT
ligands. In the nucleus, β-catenin forms functional complexes
with transcription factors of the lymphoid enhancer binding
factor-1/T-cell factor (TCF) family, activating expression of tar-Page 1 of 16
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vation of the canonical pathway by engagement of FZD and
LRP receptors, WNT ligands bind the Ror2 or Ryk receptors
to stimulate β-catenin-independent pathways that have been
involved with cytoskeletal reorganization and cell migration
[2,4].
In breast cancer, deregulation of WNT signaling appears to
occur by autocrine mechanisms [5-7]. Multiple WNT ligands
and FZD receptors are expressed in primary human breast
tumors and in breast cancer cell lines [3,7-9]. Furthermore,
most breast tumors show hypermethylation of the promoter
region of secreted Frizzled-related protein 1 (sFRP1) and low
expression of this negative WNT pathway regulator [10-12].
Interference with autocrine WNT signaling has been shown to
block in vitro proliferation of many human breast cancer cell
lines [6,7]. We have extended these studies and show in the
present article that blocking the WNT pathway in MDA-MB-
231 breast cancer cells not only decreases proliferation, but
also impairs the motility of the tumor cells. Furthermore, we
show that stable expression of sFRP1 in MDA-MD-231 cells
has a dramatic effect on the ability of the cells to grow as tumor
xenografts in nude mice. The results presented here provide
further evidence supporting approaches to target WNT path-
way activity in breast cancer.
Materials and methods
Reagents
The following primary antibodies were used: c-Myc (9E10, to
detect Myc-tagged protein), DVL2 and DVL3 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA); DVL1 (R&D Systems,
Abingdon, UK); active β-catenin (anti-ABC; Upstate, Billerica,
VA, USA); α-tubulin (DM1A) (Neomarkers, Fremont, CA,
USA); cyclin D1 (SP4) (Cell MARQUE, Rocklin, CA, USA) for
immunohistochemistry (IHC); cyclin D1 (Chemicon, Billerica,
MA, USA) for western blotting; bromodeoxyuridine (BrdU)
(Roche, Basel Switzerland); p21Cip1 (OP64-100UG) (Onco-
gene Research Products, Cambridge, MA, USA); ERK and P-
ERK (Thr202/Tyr204) (Cell Signaling Technology, Danvers,
MA, USA); total β-catenin and CD31 (BD Pharmingen, Frank-
lin Lakes, CA, USA); and active β1-integrin (Clone HUTS-4,
MAB2079Z; Chemicon).
As secondary antibodies we used anti-rabbit and anti-mouse
antibodies (GE Healthcare, Little Chalfont, UK; LI-COR Bio-
science, Lincoln, NE, USA), anti-rat antibody (GE Healthcare)
or anti-goat antibody (DAKO A/S, Glostrup, Denmark) cou-
pled to horseradish peroxidase (HRP) or IRDye 800CW.
For IHC we used Biotin-SP-conjugated affinipure donkey anti-
rabbit, anti-mouse, anti-rat IgG (Jackson ImmunoResearch,
West Grove, PA, USA) and goat anti-rat ALEXA 568 (Molec-
ular Probes, Eugene, OR, USA). Recombinant Wnt3a was
purchased from R&D Systems. Y27632 was purchased from
Sigma-Aldrich (St. Louis, MO, USA). The cDNA encoding
Myc/His-tagged human sFRP1 in pCDNA was provided by
Jeffrey Rubin (NCI, Bethesda, MD, USA) and was recloned
into the pBabePuro retroviral vector. Conditioned media (CM)
from Wnt1-producing cells, from sFRP1-producing cells, and
purified sFRP1 were prepared as previously described [7].
T-cell factor reporter assay
MDA-MB-231/sFRP1-P1 cells and control-P1 cells were
seeded on 12-well plates and were transfected with a mixture
of Super TOPFlash plasmid and pRL-CMV (Promega, Madi-
son, WI, USA) to assay TCF promoter activity using Fugene6
(Roche) according to the manufacturer's instructions. Luci-
ferase activities were measured 48 hours later using the Dual-
Luciferase Reporter Assay System (Promega) and Mithras
LB940 (Berthold Technologies, Bad Wildbad, Germany)
according to the manufacturer's instructions. The fold activa-
tion was normalized against renilla luciferase. Nine wells were
used per condition and the average and standard error are
shown in the graph.
Cell culture, transfections, retroviral infections, 
proliferation and anoikis assays
The human breast cancer cell line MDA-MB-231 (ATCC, Man-
assas, VA, USA) was cultivated in DMEM, 10% heat-inacti-
vated FCS (Amimed, Allschwil, Switzerland) supplemented
with penicillin and streptomycin (Sigma-Aldrich). All transfec-
tions were performed using FuGENE 6 Transfection Reagent
(Roche) following the manufacturer's guidelines. MDA-MB-
231 cells were stably transfected with pCDNA3.1(+) (Invitro-
gen, Carlsbad, CA, USA) encoding Myc/His-tagged human
sFRP1 or empty pCDNA3.1(+) as control. After selection with
1 mg/ml G-418, three clones of MDA-MB-231/sFRP1 and
three control clones were isolated. Equal cell numbers of
these clones were pooled before some experiments (MDA-
MB-231/sFRP1-P1 and MDA-MB-231/control-P1). A second
pool of sFRP1-expressing MDA-MB-231 cells (MDA-MB-
231/sFRP1-P2) and control cells (MDA-MB-231/control-P2),
each representing > 100 clones, was generated by infecting
the cells with pBabePuro encoding Myc/His-tagged human
sFRP1 or empty pBabePuro followed by selection with 2 μg/
ml Puromycin (Sigma-Aldrich).
Cell proliferation was measured either by counting cell num-
bers with a Vi-Cell XR cell viability analyzer (Beckman Coulter,
Fullerton, CA, USA) on selected days after seeding 200,000
cells on six-well plates or using the YOPRO cell viability assay
(Invitrogen) 3 days after seeding 1,000 cells on a 96-well
plate, according to the manufacturer's instructions. Anoikis
was measured by seeding cells in 1% FCS-containing
medium on polyHema-coated plates to prevent adhesion.
Cells were harvested 24 hours later, stained with propidium
iodide. The cell cycle distribution was analyzed with a FACS-
calibur (Becton Dickinson, San Jose, CA, USA) using the Cel-
lquest software. A representative cell cycle distribution of
three MDA-MB-231/sFRP1 clones and three control clones isPage 2 of 16
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Protein extraction and western blotting
Cells were lysed in 1% Nonidet P-40, 50 mM Tris pH 7.5, 120
mM NaCl, 5 mM ethylenediamine tetraacetic acid, 1 mM eth-
ylene glycol tetra-acetic acid (EGTA), 2 mM sodium vanadate,
20 mM β-glycerophosphate, 10 μg/ml aprotinin, 10 μg/ml leu-
peptin, 0.5 mM phenylmethanesulphonylfluoride (PMSF), 50
mM NaF, 1 mM dithiothreitol for 5 minutes on ice before col-
lecting lysates. Debris was removed by centrifugation at 4°C
and the protein concentration was determined using the Brad-
ford reagent (BioRad, Hercules, CA, USA).
For western blotting, protein loading buffer was added to 30
to 50 μg total protein and the samples were denatured for 10
minutes at 95°C prior to separation on SDS-polyacrylamide
gels and blotting by semi-dry transfer for 90 minutes on PVDF
membranes (Millipore, Billerica, MA, USA). Membranes were
blocked using 10% horse serum in Tris-buffered saline- Tween
buffer for 1 hour (0.2 M NaCl, 25 mM Tris, pH 7.5, 0.5 ml/l
Tween-20), except for p21Cip detection where PBS- Tween
buffer was used instead of TBS-Tween buffer for blocking.
Blots were incubated with primary antibodies at room temper-
ature for 1 hour or at 4°C overnight, followed by 30-minute
incubation with secondary antibodies. These antibodies were
anti-rabbit-HRP, anti-mouse-HRP (1:5000) or anti-goat-HRP
(1:5000) for detection of luminescence, which was carried out
using ECL (GE Healthcare) according to the manufacturer's
instructions and using X-OMAT LS films (Kodak, New York,
NY, USA). Secondary antibodies IRDye 800CW goat anti-rab-
bit-IgG or anti-mouse-IgG (1:10,000; LI-COR Biosciences)
were detected with the LI-COR Odyssey system according to
the manufacturer's instructions (LI-COR Biosciences). Quan-
tification of protein expression was carried out using Odyssey
2.1 (LI-COR Biosciences).
Wound healing assay
Cells were seeded on six-well plates and grown to confluency.
Monolayers were scratched, and in the indicated experiments
the media were changed to Wnt1 CM or control CM. When
using recombinant Wnt3a and Y27632, 90 minutes before the
scratch was made the media were changed to DMEM 10%
FBS containing 100 μg/ml Wnt3a (R&D Systems) and/or 5
μM Y27632 (Sigma-Aldrich). Pictures of randomly-chosen
nine wound edges per condition were taken at time 0 and at
the indicated time points using Nikon DIAPHOT (Nikon, Tokyo,
Japan). The recovered area was calculated using ImageQuant
TL (GE Healthcare). In some experiments, purified sFRP1 was
added to the CM [7].
Fluorescence-activated cell sorting analysis for active β1-
integrin
MDA-MB-231/sFRP1-P1 and control-P1 cells (0.3 × 106)
were incubated for 30 minutes on ice with an antibody recog-
nizing active β1-integrin (final concentration 20 ng/μl) in
HEPES/NaCl buffer. This was followed by incubation for 30
minutes on ice with fluorescein isothiocyanate-conjugated
(FITC) donkey anti-mouse IgG secondary antibody (Jackson
Laboratories) (diluted 1:250) in Flow PBS (1 × PBS, 2%
horse serum, 0.1% sodium azide). Fluorescence was meas-
ured using a FACSCalibur machine (Becton Dickinson) and
the percentage of gated cells stained with active β1-integrin
was calculated.
In vivo experiments with MDA-MB-231 cells
Female Balb/c nude mice 7 to 10 weeks old were obtained
from Charles River Laboratories (L'Arbresle, France) and were
maintained in accordance with the Swiss guidelines for animal
safety. Mammary tumors were established in mice (5 to 8 mice
per group) by injecting 0.5 to 1.0 × 106 control or sFRP1-
expressing MDA-MB-231 cell lines in 100 to 150 μl PBS into
the fourth right-side mammary fat pad. The tumor size was
measured two or three times per week using a gage, and the
volume was calculated considering the tumor as an oval
according to the formula:
Statistical analyses were performed with two-way repeated-
measures analysis of variance (repeated measures ANOVA
(RM ANOVA)).
To assay tumor cell proliferation, 100 μg/g body weight of
BrdU (Cell Proliferation Kit II; Roche) was intraperitoneally
injected into tumor-bearing mice that were sacrificed 2 hours
later. Tumors were excised and washed with PBS before fixa-
tion in 4% paraformaldehyde (PFA) at 4°C for 24 hours, and
BrdU detection was performed as previously described [13].
To examine experimental metastasis, 1.0 × 106 MDA-MB-231/
sFRP1-P2 cells or control-P2 cells were injected into the tail
vein of female Balb/c nude mice (5 to 6 mice per group). Fifty-
three days after the injection, the mice were sacrificed, lungs
were dissected and the total number of surface lung metas-
tases was determined. For western analyses, excised tumors
were snap frozen and pulverized in liquid nitrogen and lysed in
SDS buffer (100 mM Tris- HCl pH 7.6, 2% SDS, 10 mM dithi-
othreitol, 2 mM sodium vanadate, 0.5 mM ethylenediamine
tetraacetic acid) by incubation at 95°C for 10 minutes.
Immunohistochemistry and functional vessel analysis on 
tumor sections
To detect functional vessels in tumors, 100 μl of 2 μg/μl solu-
tion of fluorescein-labeled Lycopersicon esculentum lectin
(Vector Labs, Burlingame, CA, USA) was injected into tail
veins of tumor-bearing mice [14], and the mice were sacrificed
5 minutes later. Tumors were excised, fixed in 4% paraformal-
dehyde in PBS for 48 hours at 4°C, followed by an overnight
incubation in 30% sucrose in PBS at 4°C, and then embed-
ded in tissue-Tec O.C.T. Compound 4583 (Sakura, Tokyo,
4 2 2 32π[( / )( / ) ]/longer edge shorter edgePage 3 of 16
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to detect tumor-associated vessels using rat anti-mouse
CD31 (diluted 1:100; BD Pharmingen) and goat anti-rat
ALEXA 568 (diluted 1:200; Molecular Probes). Staining was
performed using Discovery XT (Ventana Medical Systems,
Inc., Tucson, AZ, USA). Pictures were taken with a Z1 micro-
scope (Carl Zeiss, Jena, Germany) and were analyzed with
IMARIS (Bitplane, Zurich, Switzerland) to calculate the co-
localized area. For detection of cyclin D1, frozen tumor sec-
tions (9 μm) were subjected to IHC using SP4 (diluted 1:100)
and Biotin-SP-conjugated affinipure donkey anti-rabbit IgG
(diluted 1:100). Staining was carried out using Discovery XT
with sCC1 pretreatment. Pictures were taken with an Eclipse
E600 (Nikon) and were analyzed with IMARIS (Bitplane) to
calculate the signal intensity.
RNA isolation, real-time PCR and microarray analyses
Cultured cells were collected when plates were 70 to 80%
confluent and total RNA was extracted using the RNeasy Mini
kit (Qiagen, Venlo, The Netherlands). To extract total RNA
from tumors, dissected tumors were put into RNAlater (Qia-
gen) overnight at 4°C, followed by RNA extraction using TRIzol
reagent (Invitrogen) and washing using the RNAeasy Mini kit
according to the manufacturer's instructions. RNA from mam-
mary tumors (six MDA-MB-231/sFRP1-P1 tumors and five
control tumors) and cultured cells (three MDA-MB-231/
sFRP1 clones and three control clones) were individually
amplified and labeled using the Ambion MesageAMP III RNA
Amplification Kit (Applied Biosystems, Austin, TX, USA). Bioti-
nylated, fragmented cRNA was hybridized to Affymetrix U133
plus 2.0 human GeneChips™ (Affymetrix, Santa Clara, CA,
USA).
Expression values were estimated using the GC-RMA imple-
mentation found in Genedata's Refiner 4.5 software (Gene-
data AG, Basel, Switzerland). Quantile normalization and
median scaling were performed in order to standardize array
signal distributions to facilitate the comparison between in
vitro cultured cells and in vivo tumor samples. Probesets
showing statistically different expression profiles (one-way
analysis of variance with P < 0.01; Benjamini and Hochberg Q
values determined to minimize the false discovery rate) and
specific pairwise fold changes were clustered by rank correla-
tion with R > 0.8 for the first criterion and R > 0.885 for the
second criterion using the Profile Distance Search function of
Genedata's Analyst 4.5 tool (Genedata AG, Basel, Switzer-
land). All of the microarray data are stored in Gene Expression
Omnibus [GEO:GSE13806].
For the quantitative real-time PCR, each sample cDNA was
made from 2.5 μg RNA using Ready-To-Go™ You-Prime First-
Strand Beads (GE Healthcare). Quantitative real-time PCR
was performed with ABI Prism 7000 (Applied Biosystems,
Austin, TX, USA) using ABsolute SYBR Green ROX Mix
(THERMO Scientific, Waltham, MA, USA) following the man-
ufacturer's guidelines. The primer sequences used for quanti-
tative real-time PCR are as follows: human c-Myc forward, 5'-
CCTACCCTCTCAACGACAG-3'; human c-Myc reverse, 5'-
CTTGTTCCTCCTCAGAGTCG-3'; human β-actin forward,
5'-TGTCCACCTTCCAGCAGATGT-3'; and human β-actin
reverse, 5'-CGCAACTAAGTCATAGTCCGCC-3'.
Results
Ectopic sFRP1 expression in MDA-MB-231 cells blocks 
WNT signaling
Interference with autocrine WNT signaling via sFRP1 has
been shown to block in vitro proliferation of human breast can-
cer cell lines [6,7]. In the following experiments we examined
the effects of blocking WNT signaling using the basal-like
breast cancer model MDA-MB-231 [15]. Vectors encoding
Myc-tagged sFRP1 and the empty control were transfected
into MDA-MB-231 cells, which express no sFRP1 mRNA
(data not shown), and stable clones were selected in G418-
containing medium. Three MDA-MB-231/sFRP1 clones
expressing moderate to strong levels of the Myc-tagged
sFRP1, as well as control clones, were selected for further
analyses (Figure 1a).
WNT pathway activity was examined in the cells using various
markers. As a consequence of WNT binding to FZD, cytoplas-
mic scaffolding proteins of the Dishevelled family (DVL1,
DVL2 and DVL3) become phosphorylated on serine and thre-
onine residues. DVL phosphorylation, which is the most proxi-
mal signaling event downstream of FZD activation, can be
monitored by a decrease in the electrophoretic mobility of p-
DVL [16,17]. DVL1, DVL2 and DVL3, total β-catenin and sta-
bilized active β-catenin were examined by western analysis in
the individual clones. In the sFRP1-expressing cells, there was
a decrease in the level of the three p-DVLs, compared with the
vector control cells. Furthermore, the level of total β-catenin
and active β-catenin was reduced in the two clones express-
ing the highest level of sFRP1 (Figure 1a).
Next we examined transcriptional activity of the canonical
WNT signaling pathway following transient expression of the
TOPFlash TCF reporter plasmid in the cells. TOPFlash luci-
ferase reporter activity showed a significant 2.7-fold decrease
in the sFRP1-expressing cells compared with controls (Figure
1b), confirming that ectopic expression of sFRP1 reduces
canonical pathway activity in MDA-MB-231 cells. The phos-
phorylation status of ERK, another signaling protein that is
active in MDA-MB-231 cells, was not altered in the sFRP1-
expressing cells (Figure 1a), suggesting that the effects of
sFRP1 are specific for the WNT pathway.
For further studies, the three sFRP1-expressing clones were
pooled (P1) and a second pool of sFRP1-expressing MDA-
MB-231 cells consisting of > 100 clones was generated (P2).
Corresponding control pools, control-P1 and control-P2, were
also generated. Quantification of a western analysis showsPage 4 of 16
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sFRP1 than does MDA-MB-231/sFRP1-P2 (Figure 1c).
sFRP1 decreases proliferation of MDA-MB-231 cells
Next we examined effects of sFRP1 on tumor cell proliferation.
MDA-MB-231 parental cells were inhibited by treatment with
sFRP1 CM (see Additional data file 1). Furthermore, ectopic
expression of sFRP1 in MDA-MB-231 cells also caused a
decrease in proliferation (Figure 1d, e). One day after plating
there was no significant difference between the control cells
and the sFRP1-expressing cells. After 3 days, however, we
observed a significant difference in the sFRP1-P1 cells and
sFRP1-P2 cells compared with control cultures. This effect
appears to be dependent on sFRP1 expression levels since, in
Figure 1
Ectopic expression of sFRP1 in MDA-MB-231 breast cancer cells. (a) Western analysis was performed on lysates of three MDA-MB-231/secreted 
Frizzled-related protein 1 (sFRP1) clones and three MDA-MB-231/control clones and the levels of active β-catenin, total β-catenin, α-tubulin and 
DVL1 to DVL3 determined with specific antisera. Myc-tagged sFRP1 was detected with a Myc-specific antiserum. Lower panel: level of total ERK1/
2 and P-ERK1/2 in a MDA-MB-231/sFRP1 clone and a MDA-MB-231/control clone. (b) Activity of the WNT/β-catenin pathway was measured 
using the TOPFlash T-cell factor reporter system. MDA-MB-231/sFRP1-P1 and control-P1 cells were transiently co-transfected with the TOPFlash 
reporter plasmid and a pRL-CMV control plasmid, and the reporter activity was measured 48 hours later with a luminometer. y axis, TOPFlash 
reporter activity normalized by pRL-CMV control activity (arbitrary units), average ± standard error. *P < 0.05. (c) Level of Myc-tagged sFRP1 in two 
pools of MDA-MB-231/sFRP1 cells determined by western analysis using a Myc-specific antiserum. α-Tubulin levels served as a control. P1 is a mix-
ture of the three clones shown in (a); P2 was generated from > 100 sFRP1-infected clones. (d) MDA-MB-231/sFRP1-P1 and (e) MDA-MB-231/
sFRP1-P2 and control-P1 and control-P2 were seeded on six-well dishes (200,000 cells/well) in DMEM, 10% FCS. After 1 day and 3 days, three 
wells per condition were counted and the average cell numbers were calculated ± standard error of the mean. **P < 0.01, *P < 0.05, n.s. = not sig-
nificant.Page 5 of 16
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in proliferation of MDA-MB-231/sFRP1-P1 (Figure 1d) and
MDA-MB-231/sFRP1-P2 (Figure 1e) cells at day 3, respec-
tively.
Xenografts of sFRP1-expressing MDA-MB-231 cells 
show reduced growth in nude mice
To test the in vivo effects of sFRP1 expression, control and
sFRP1-expressing MDA-MB-231 cells were injected into the
mammary fat pads of female nude mice and tumor growth was
monitored. There was a significant reduction in tumor out-
growth in mice injected with MDA-MB-231/sFRP1-P1 cells
compared with control cells (P < 0.01, two-way RM ANOVA)
(Figure 2a). Furthermore, the time to detection of the first
tumors was much shorter after injection of MDA-MB-231/con-
trol-P1 cells, compared with MDA-MB-231/sFRP1-P1 cells
(23 days vs. 35 days, respectively) (Figure 2b). Moreover,
three mice injected with the MDA-MB-231/sFRP1-P1 cells
remained tumor-free at day 45, when the experiment was ter-
minated. In contrast, all of the mice injected with MDA-MB-
231/control-P1 cells had tumors (Figure 2b). Western analy-
sis carried out on tumor lysates revealed that sFRP1 was
present in tumors arising from MDA-MB-231/sFRP1-P1 cells
and WNT signaling was downregulated, since there was a
decrease in the amount of p-DVL3 in comparison with control
tumors (Figure 2c).
MDA-MB-231/sFRP1-P1 cells were tested in two additional
experiments that yielded similar results (see Additional data file
2). While there was some variation in the time of tumor onset
in the individual experiments, the time to appearance of the
first tumor was consistently longer following injection of the
MDA-MB-231/sFRP1 cells, in comparison with control cells
(Figure 2b; see Additional data file 2). The data pertaining to
the number of tumor-free mice were pooled for the three
experiments, showing that 68% of the mice injected with
MDA-MB-231/sFRP1-P1 cells were tumor-free at day 39,
while only 20% of the control animals were free of tumors (Fig-
ure 2d). The data on tumor outgrowth kinetics were pooled for
two experiments (Figure 2e), yielding a highly significant differ-
ence in the outgrowth ability of sFRP1-expressing cells (P <
0.0001, two-way RM ANOVA).
MDA-MB-231/sFRP1-P2 cells, which express 2.8-fold less
sFRP1 than do the MDA-MB-231/sFRP1-P1 cells (Figure 1c),
also grew more slowly than control cells following injection in
the mammary gland (Figure 2f). Although the effect on tumor
growth did not reach significance using two-way RM ANOVA
and all animals had tumors at the end of the experiment (Figure
2g), tumor onset was delayed significantly in the cohort
injected with MDA-MB-231/sFRP1-P2 cells (P = 0.026, log-
rank test) (Figure 2g). The in vivo results together with the data
on in vitro proliferation (Figure 1d, e) suggest that higher levels
of sFRP1 cause a stronger blockade of WNT pathway activity,
leading to a more pronounced effect on the time to tumor
onset and tumor outgrowth.
MDA-MB-231/sFRP1-expressing cells have a lower 
migratory ability and form fewer metastases
Acquisition of migratory ability by cancer cells is an important
characteristic contributing to metastatic tumor cell spread
[18]. Accordingly, we also examined the effect of WNT signal-
ing on the migratory ability of MDA-MB-231 cells, using a
wound healing assay. Confluent monolayers of MDA-MB-231/
sFRP1-P1 cultures and control-P1 cultures were scratched
and the medium was changed to Wnt1 CM or control CM. In
response to Wnt1 CM, the control MDA-MB-231 cells
migrated significantly more rapidly into the wounded area
compared with cultures treated with control CM (Figure 3a,
gray bars). In contrast, Wnt1 treatment of MDA-MB-231/
sFRP1-P1 cells did not significantly stimulate migration (Fig-
ure 3a, black bars), reflecting the ability of sFRP1 to block
Wnt1-mediated FZD activation.
We also performed a migration assay using the parental MDA-
MB-231 cells treated with purified recombinant Wnt3a to con-
firm the results obtained with Wnt1 CM (recombinant Wnt1 is
not commercially available). Wnt3a stimulated the canonical
pathway as shown by the increased level of active β-catenin
(Figure 3b), and increased the migratory ability of the cells in a
wound closure assay (Figure 3c). In summary, in MDA-MB-
231 cells, activation of the WNT pathway has a positive effect
on cell migration; while sFRP1 lowers the proliferative and
migratory ability of the MDA-MB-231 cells.
Next we tested the effect of WNT pathway blockade on the in
vivo metastatic ability of MDA-MB-231 cells. Populations of
MDA-MB-231/sFRP1 cells and control cells were injected
into nude mice through the tail vein [19]; 53 days later the
mice were sacrificed and the lungs were analyzed for meta-
static foci. There was a dramatic difference in the number of
metastatic foci arising from sFRP1-expressing cells compared
with control cells. A typical lung from an animal injected with
control MDA-MB-231 cells and with sFRP1-expressing cells
is shown (Figure 4a). A quantitative analysis of the lungs
revealed that there is a significant decrease in the number of
metastases arising in mice injected with sFRP1-expressing
cells in comparison with control MDA-MB-231 cells (Figure
4b). In conclusion, sFRP1-mediated blockade of WNT signal-
ing impairs the in vitro migratory ability and the in vivo meta-
static ability of MDA-MB-231 tumor cells.
Mechanisms contributing to the in vivo anti-tumor 
effects of sFRP1
Our next goal was to uncover the mechanism underlying the
ability of sFRP1 to decrease the mammary tumor-forming
potential of MDA-MB-231 cells. This could be tumor cell intrin-
sic, resulting from downregulation of WNT signaling, and/or
extrinsic via secreted sFRP1 effects on tumor-associatedPage 6 of 16
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ation was evaluated by examining BrdU incorporation in con-
trol tumors and sFRP1-expressing tumors. Incorporated BrdU
was detected with a specific antiserum (Figure 5a) and stain-
ing was quantified. There was a 70% reduction in BrdU stain-
ing in tumors arising from MDA-MB-231/sFRP1-P1 cells
compared with control tumors (Figure 5b). Apoptosis, as
measured by western blotting for cleaved caspase-3, was low
in the MDA-MB-231 control tumor lysates and was not
increased in the MDA-MB-231/sFRP1-P1 tumor lysates (data
Figure 2
Ectopic expression of sFRP1 in MDA-MB-231 cells suppresses in vivo tumor formation. (a), (b) MDA-MB-231/secreted Frizzled-related protein 1 
(sFRP1)-P1 cells and control cells (1 × 106) were injected into mammary fat pads of the indicated number of Balb/c nude mice, and the tumor for-
mation and growth were monitored: (a) average tumor volume, P < 0.01 (two-way repeated-measures analysis of variance (RM ANOVA)); (b) per-
centage of tumor-free mice on the indicated days after injection, P = 0.0106 (log-rank test). (c) Lysates prepared from individual tumors at the end 
of the experiment were monitored for Myc-tagged sFRP1 (upper panel) and for p-DVL3 and DVL3 (lower panel) by western analyses. (d) Three inde-
pendent xenograft experiments using MDA-MB-231/sFRP1-P1 cells (n = 19) and control-P1 cells (n = 20) were performed and data were pooled to 
calculate the percentage of tumor-free mice 39 days after the injection. (e) Data from the indicated number of mice generated in two independent 
xenograft experiments with MDA-MB-231/sFRP1-P1 cells and control-P1 cells ((a) and Additional data file 2, Figure 2a) were pooled to yield the 
tumor growth curve, P < 0.0001 (two-way RM ANOVA). (f), (g) MDA-MB-231/sFRP1-P2 cells and control P2 cells (1 × 106) were injected into 
mammary fat pads of the indicated number of Balb/c nude mice, and tumor formation and growth were monitored: (f) average tumor volume, *P < 
0.01 on day 19 (Student's t test); (g) percentage of tumor-free mice on the indicated days after injection, P = 0.026 (log-rank test). (a), (d), (e) Tumor 
growth curves shown as the average tumor volume ± standard error.Page 7 of 16
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cells did not render them sensitive to anoikis-induced cell
death (Figure 5c), which rules out the possibility that slower
tumor outgrowth reflects lower numbers of viable cells at the
time of inoculation. In summary, the results suggest that
sFRP1 downregulation of WNT signaling has a strong effect
on tumor cell proliferation, but not on survival.
sFRP1 has been reported to block in vivo neovascularization
[20]. We therefore considered the possibility that the density
or the functionality of the tumor-associated vessels might be
impaired in sFRP1-expressing tumors. Vasculature was visual-
ized by tail vein injection of tumor-bearing mice with FITC-
labeled L. esculentum lectin [14] 5 minutes before the animals
were sacrificed, which allows only functional vessels to be per-
Figure 3
WNT promotes MDA-MB-231 cell migrationll i r ti . (a) Confluent monolayers 
of MDA-MB-231/secreted Frizzled-related protein 1 (sFRP1)-P1 cells 
and control-P1 cells were scratched, the medium was changed to 
Wnt1 conditioned medium (CM) or control CM, and 3 hours later the 
recovered areas were calculated on nine randomly chosen wound 
edges. Results presented in arbitrary units. Average recovered areas 
calculated ± standard error of the mean (SEM). **P < 0.01, n.s. = not 
significant (P > 0.05). (b) MDA-MB-231 cells were treated with 100 
ng/ml recombinant Wnt3a for the indicated time. Active β-catenin was 
detected by western analysis using specific antiserum; α-tubulin level 
serves as a loading standard. (c) Confluent monolayers of MDA-MB-
231 cells cultured in DMEM, 10% FCS were changed to DMEM, 10% 
FCS with or without 100 ng/ml recombinant Wnt3a, and 90 minutes 
later the monolayer surface was scratched. The recovered area was 
measured on nine randomly chosen wound edges, 3 and 6 hours later. 
y axis, recovered area (arbitrary unit) ± SEM. **P < 0.01.
Figure 4
sFRP1 inhibits the metastatic potential of MDA-MB-231 tumor cells. 
MDA-MB-231/secreted Frizzled-related protein 1 (sFRP1)-P2 cells or 
control-P2 cells (1 × 106) were injected into five and six Balb/c nude 
mice, respectively, through the tail vein; 53 days later the mice were 
sacrificed and the lungs were dissected. (a) Representative picture of 
lungs from the mice injected with MDA-MB-231/sFRP1-P2 cells (left) 
and control-P2 cells (right); arrow, metastatic lesion. (b) The total 
number of lung surface metastases was determined for all the mice and 
the average is shown ± standard error of the mean. **P < 0.01.Page 8 of 16
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Figure 5
Analysis of proliferation and tumor angiogenesis in MDA-MB-231/sFRP1 xenografts. (a) Mice bearing MDA-MB-231/secreted Frizzled-related pro-
tein 1 (sFRP1)-P1 or control-P1 tumors were injected with bromodeoxyuridine (BrdU) and sacrificed 2 hours later. Tumors of similar weight from 
each group were sectioned and stained with anti-BrdU antibody. Bar = 250 μm. (b) BrdU-positive nuclei and total nuclei were counted in nine ran-
domly chosen areas from each section. Bar graph shows the quantification ± standard error of the mean (SEM). **P < 0.01. (c) Aniokis assays were 
performed by seeding cells in 1% FCS-containing medium on polyHema-coated plates to prevent adhesion. Cells were harvested 24 hours later, 
stained with propidium iodide and analyzed with a FACScalibur. Representative cell cycle distribution of three independent control and sFRP1-
expressing MDA-MB-231 clones shown. (d) Total blood vessels in tumor sections visualized by staining for the endothelial cell marker CD31. y axis, 
ratio of CD31+ area/total area. Average calculated from five sFRP1-expressing and eight control tumors ± SEM. n.s., not significant. (e) Functional 
blood vessels in tumor-bearing mice visualized by injecting FITC-lectin into tail veins 5 minutes before sacrificing. The FITC+ and CD31+ areas were 
measured on tumor sections and the average was calculated on three sFRP1-expressing and five control tumors. y axis, FITC+ area/CD31+ area 
ratio ± SEM. n.s., not significant. (d), (e) Image analysis performed using IMARIS software (Bitplane).
Breast Cancer Research    Vol 11 No 3    Matsuda et al.fused. Tumor sections were prepared and the associated
endothelial cells were stained for CD31, while functional ves-
sels were visualized via the FITC signal. There was no signifi-
cant difference in the total vessel area or the ratio of FITC-
positive/CD31-positive vessels in sFRP1-expressing tumors
compared with control tumors (Figure 5d, e), suggesting that
sFRP1 does not influence the number or the functionality of
tumor-associated blood vessels. In summary, these results
suggest that sFRP1-mediated blockade of WNT pathway
activity in tumor cells is an important factor contributing to the
slower outgrowth of the MDA-MB-231/sFRP1 tumors in mam-
mary glands.
Identification of genes whose expression level is 
selectively altered in vivo in sFRP1-expressing tumors
To identify target genes that are controlled by sFRP1 expres-
sion and might influence proliferation of the MDA-MB-231
cells, we undertook a genome-wide transcriptome analysis
using microarrays. RNA isolated from individual tumors arising
after injection of MDA-MB-231/sFRP1-P1 cells and control-
P1 cells, as well as RNA from in vitro cultured MDA-MB-231/
sFRP1-P1 cells and control-P1 cells, was analyzed.
Considering data generated from six sFRP1-expressing
tumors and five control tumors, there were 1,753 probesets
(1,246 genes) whose signals changed more than 1.5-fold (P
< 0.01, Student's t test) in the tumors arising from MDA-MB-
231/sFRP1-P1 cells compared with tumors arising from con-
trol-P1 cells. The same analysis performed on in vitro cultured
samples revealed 428 probesets (332 genes) that had a 1.5-
fold difference (P < 0.01, Student's t test). Only 69 probesets
(54 genes) overlapped between the two analyses, clearly
showing the substantial difference in gene expression
between in vivo tumors and in vitro cultured cells.
All of the microarray data were examined for characterized
WNT pathway target genes. We identified 16 genes where at
least one of the probesets showed a tendency for suppression
in MDA-MB-231/sFRP1-expressing cells and tumors (see
Additional data files 3 and 4).
Cell cycle regulators are altered in sFPR1-expressing 
MDA-MB-231 xenografts
In vitro proliferation of MDA-MB-231/sFRP1-P1 cells was
decreased by 30% compared with control cultures (Figure 1),
while the in vivo effects of WNT pathway blockade appeared
to be much stronger. For example, in comparison with control
MDA-MB-231 cells, outgrowth of MDA-MB-231/sFRP1-P1-
generated tumors was significantly slower; and tumor-free
mice remained in this cohort in each experiment (Figure 2). We
therefore decided to identify transcripts that were only altered
in vivo in MDA-MB-231/sFRP1-expressing tumors. We
screened the previously mentioned 1,753 probesets that were
originally identified by a comparison of the MDA-MB-231/
sFRP1 tumors with control tumors (see above) using the Pro-
file Distance Search function of Genedata's Analyst 4.5 tool.
In this analysis we looked for genes whose expression was
significantly altered only in tumors arising from MDA-MB-231/
sFRP1-P1 cells compared with tumors arising from control-P1
cells, with cultured MDA-MB-231/sFRP1-P1 cells or with cul-
tured control-P1 cells. This resulted in 135 probesets (106
genes) that were downregulated (Figure 6a) and 84 probesets
(62 genes) that were upregulated (Figure 6b) only in the
sFRP1-positive tumors (see Additional data files 5 and 6 for
lists of genes and their fold change).
The microarray analysis showed that the signal from a
probeset for CCND1 (encoding cyclin D1) was downregu-
lated and the probeset for CDKN1A (gene encoding p21Cip1)
was upregulated in vivo, in tumors resulting from MDA-MB-
231/sFRP1-P1 cell injection (Figure 6c). The CCND1 pro-
moter has a consensus lymphoid enhancer binding factor-1
binding site [21], and in some cancer models its expression is
controlled by β-catenin/TCF activation [22]. Our results sug-
gest that CCND1 might also be a direct β-catenin/TCF target
in MDA-MB-231 cells.
Both of these genes were analyzed further based on their
known roles in cell cycle regulation and proliferation. Cyclin D1
was examined by IHC in tumor sections using a specific
antiserum. Quantification of the staining showed a 30%
decrease in cyclin D1 in sFRP1-expressing tumors compared
with control tumors (Figure 7a). Western analysis for cyclin
D1, carried out on lysates prepared from MDA-MB-231/
sFRP1-P1 cultures and control cultures, revealed no signifi-
cant difference in expression (Figure 7b). Western analysis
revealed that p21Cip1 was present in tumors resulting from
injection of MDA-MB-231/sFRP1-P1 cells, while none was
detectable in control tumors (Figure 7c). Considering the in
vitro cultured cells, neither MDA-MB-231/sFRP1-P1 cells nor
control-P1 cells had detectable levels of p21Cip1 protein (Fig-
ure 7d). As predicted from the array data (Figure 6c), there-
fore, the decrease in cyclin D1 and the increase in p21Cip1 are
observed in vivo in the sFRP1-expressing tumors.
Considering that c-Myc is a WNT pathway target [23,24] that
regulates cyclin D1 [22] and p21Cip1 expression [25], we also
examined c-Myc. There were no significant changes in c-Myc
RNA levels in sFRP1-expressing tumors; however, c-Myc pro-
tein levels were lower in all of the sFRP1-expressing tumors
compared with the control tumors (see Additional data file 7).
In summary, the in silico analysis carried out on RNA of tumors
arising from the MDA-MB-231/sFRP1 cells revealed altered
levels of target genes (CCND1 and CDKN1A) that probably
contribute to the anti-proliferative effects of sFRP1 expression.
Moreover, our results also show the strong influence that the
in vivo tumor environment has, not only on gene expression,
but also on c-Myc protein. Decreased c-Myc levels might also
contribute to the in vivo activity of sFRP1.Page 10 of 16
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Aberrant activation of WNT signaling plays an important role in
many types of human cancer, warranting therapeutic
approaches to target the pathway [26]. Wnt1 was the first
identified oncogene activated by mouse mammary tumor virus
insertional mutagenesis [27], establishing the potential of
aberrant WNT expression to promote mammary cancer. Cur-
rently, it is well documented that multiple WNT ligands and
FZD receptors are expressed in primary human breast tumors
and breast cancer cell lines [3,7-9], making it difficult to iden-
tify an individual ligand/receptor complex that could serve as a
cancer target. Using broad antagonists – including the
Figure 6
Microarray analysis comparing gene expression profiles generated from tumors and from in vitro cultured cells. (a) y axis, 135 probesets (106 
genes) showing low expression in secreted Frizzled-related protein 1 (sFRP1)-positive tumors and moderate-high expression in control tumors, in in 
vitro cultured sFRP1-positive and in control cells. (b) y axis, 84 probesets (62 genes) showing high expression in sFRP1-positive tumors, and low 
expression in control tumors, in in vitro cultured sFRP1-positive and in control cells. (a), (b) Left to right, columns represent six sFRP1-positive 
tumors, five control tumors, three MDA-MB-231/sFRP1 clones and three MDA-MB-231/control clones (from Figure 1a). Genes with high, moderate 
and low expression are indicated in red, black and green, respectively. (c) Normalized gene expression of CCND1 and CDKN1A in MDA-MB-231/
sFRP1-P1 and control-P1 tumors, and in MDA-MB-231/sFRP1-P1 and control P1 in vitro cultured cells.Page 11 of 16
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[6,7,29] – to interfere with WNT/FZD binding, however, the
potential of targeting WNT binding to FZD as a therapeutic
approach in breast cancer [6,7] and in other cancers [28,30]
has been demonstrated.
Aberrant methylation of the sFRP1 promoter is one of the most
consistent alterations in human cancer. In addition to breast
tumors that have low sFRP1 levels [10-12,29,31], sFRP1 sup-
pression has been described in colon tumors [32], ovarian
tumors [33], bladder tumors [34] and prostate tumors [35].
Based on its widespread loss, interest in testing the effects of
sFRP1 treatment in tumor models has been high. Indeed,
Figure 7
Detection of cyclin D1 and p21Cip1 in tumors and in cultured cells. (a) Tumor sections from mice bearing MDA-MB-231/secreted Frizzled-related 
protein 1 (sFRP1)-P1 and control tumors were stained with cyclin D1-specific antiserum. Signal intensities, shown in the bar graph, reflect data col-
lected from six MDA-MB-231/sFRP1-P1 tumors and eight control tumors ± standard error of the mean (SEM). *P < 0.05. (b) Cyclin D1 detected in 
lysates from in vitro cultured MDA-MB-231/sFRP1-P1 cells and control cells by immunoblotting. Bar graph: levels were quantified from three MDA-
MB-231/sFRP1 and three control clones (from Figure 1a). Average ± SEM, n.s. = not significant. (c) p21Cip1 detected in tumor lysates from five 
MDA-MB-231/sFRP1-P1 tumors and three control tumors. (d) Lysates from in vitro cultured MDA-MB-231/sFRP1-P1 and control-P1 cells had no 
detectable p21Cip1. Lysates from MCF7 control and siRNA-mediated p21Cip1 knockdown tumor cells served as positive and negative controls, 
respectively; α-tubulin served as loading control.Page 12 of 16
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erties of breast cancer cells [6,29] and cervix cancer cells
[36]; while sFRP2 has been shown to block proliferation of
gastric cancer cells [37]. We have previously shown that pro-
liferation of the estrogen-receptor-positive MCF7 and T47D,
and the ErbB2-overexpressing JIMT-1, SKBR3 and BT474
breast tumor cell lines is decreased following treatment with
sFRP1 [7]. In the current study we tested the impact of
ectopic sFRP1 expression in the aggressive, basal-like [15]
MDA-MB-231 breast tumor cells. The results presented show
that ectopic sFRP1 expression in MDA-MB-231 tumor cells
blocks the migratory ability and the proliferative potential of the
tumor cells, both in vitro and in vivo, supporting the proposal
that blockade of WNT signaling with sFRP1 might be a gen-
eral approach to target not only breast, but also other types of
cancer.
In addition to testing sFRP1, we also examined the effects of
specific Wnt ligands on motility and found that the canonical
ligands Wnt1 and Wnt3a stimulate MDA-MB-231 cells in a
wound closure assay. These results correlate well with the
stimulatory effects of both Wnt ligands in other cellular models
[38,39]. The Wnt/PCP pathway is considered the major medi-
ator of cell motility. Indeed, this pathway stimulates many
cytoskeleton regulators, including Rho family GTPases and
Rho kinase [40]. Both Wnt1 and Wnt3a have been shown to
activate RhoA [38,39], whereas the non-canonical Wnt5a pro-
motes melanoma migration via RhoB [41]. Furthermore, Rho
kinase inhibition has been shown to block the effects of Wnt3a
[39]. We have also observed that the Rho kinase inhibitor
Y27632 blocks Wnt3a-induced MDA-MB-231 wound closure
(data not shown). In contrast to the positive effects of Wnt lig-
ands on motility, we show here that sFRP1-mediated blockade
of endogenous WNT signaling not only reduced the basal
motility of the MDA-MB-231 cells, but also impaired the ability
of the cells to respond to Wnt1 in a wound closure assay.
sFRP1 has also been shown to block motility [39] and invasion
[36] of other types of tumor cells. Importantly, the negative
impact of sFRP1 on MDA-MB231 motility translated, in vivo,
to a block in the metastatic potential of these aggressive
breast tumor cells. In comparison with control MDA-MB-231
cells, we observed a 20-fold decrease in the number of lung
metastasis arising from sFRP1-expressing MDA-MB-231
cells.
MDA-MB-231/sFRP1 cells also proliferated more slowly than
control cells; however, the effect of sFRP1 was more striking
in vivo than in vitro. Following injection of MDA-MB-231/
sFRP1 cells into mammary glands of nude mice, the time to
appearance of the tumors was consistently longer than that
observed with control MDA-MB-231 cells. Furthermore,
tumors generated by the sFRP1-expressing cells not only
grew more slowly than control tumors, but there were threefold
more tumor-free mice at the end of each experiment in this
group. Since sFRP1 is a secreted protein, it could act extrinsi-
cally on cells in the tumor environment. We concentrated in
particular on tumor-associated vessels based on the reported
ability of sFPR1 to block in vivo neovascularization [20]. Nei-
ther the vessel number nor their functionality differed, how-
ever, in tumors generated by sFRP1-expressing cells in
comparison with those of control MDA-MB-231 cells. The
impact of sFRP1 on WNT signaling and downstream tran-
scription in the MDA-MB-231 cells might therefore more prob-
ably explain the protein's strong in vivo effects. Indeed, there
were 3.7-fold more genes whose transcription was altered by
sFRP1 expression in vivo compared with in vitro (1,246 vs.
332). Furthermore, only 54 genes overlapped in the two lists.
Taken together, these results demonstrate the strong impact
of tumor environment on gene expression.
We also performed an in-depth analysis to identify genes that
were only affected in vivo, in the sFRP1-expressing tumors,
with the intention of finding potential targets that could
account for the strong effect of sFRP1 on MDA-MB-231
tumor-forming potential. There were a total of 168 genes (106
downregulated genes and 62 upregulated genes) that were
only affected in vivo in sFRP1-expressing tumors (see Addi-
tional data files 5 and 6). Changes in expression of two in vivo
identified genes, CCND1 and CDKN1A, encoding important
cell cycle regulators were confirmed by IHC and immunoblot-
ting on tumor cells. Cyclin D1 and p21Cip1 were found to be
downregulated and upregulated, respectively, only in sFRP1-
expressing tumors, which might be one reason why the impact
of sFRP1 expression is stronger in vivo. These results raise the
question as to why CCND1 and CDKN1A were only affected
in vivo. While we can only speculate at this time, two explana-
tions are worth discussion. First, c-Myc, which controls
expression of both genes, was only downregulated in the
sFRP1-expressing tumors; second, in the tumors there were
major changes in expression of probesets for extracellular
matrix proteins.
MYC is WNT pathway target [23,24]. We did not detect
changes in MYC expression, however, either in the microar-
rays (see Additional data files 5 and 6) or by quantitative real-
time PCR (see Additional data file 7). Interestingly, c-Myc pro-
tein was low in all of the sFRP1-expressing tumors (see Addi-
tional data file 7). C-Myc is subject to control at many levels
[42,43] and the fact that c-Myc protein only changed in the
sFRP-1-expressing tumors could be a reflection of the in vivo
environment. Irrespective of the mechanism underlying these
results, the fact that c-Myc stimulates cyclin D1 expression
[22] and is a repressor for p21Cip1 [25] suggests that lower c-
Myc levels could contribute to the altered expression of both
cell cycle regulators in sFRP1-expressing tumors.
Turning to the extracellular matrix components, probesets for
fibronectin, laminins and collagens were found to be strongly
altered (see Additional data file 8, 29 probesets for the extra-
cellular matrix). As expected, FN1 – a WNT pathway targetPage 13 of 16
(page number not for citation purposes)
Breast Cancer Research    Vol 11 No 3    Matsuda et al.(see Additional data files 3 and 4) – was decreased in sFRP1-
expressing cells and tumors. The most striking difference,
however, was seen when comparing the signal of the 29
probesets in cultured cells versus tumors. On the one hand,
25 out of the 29 probesets (see Additional data file 8) were
strongly increased in vivo in control tumors, showing the
impact of the tumor environment on expression of the encoded
genes. Moreover, 21 out of these 25 were downregulated in
sFRP1-expressing tumors.
Fibronectin, laminin and collagen are ligands for β1-integrin,
which was also suppressed in sFRP1-expressing cells (see
Additional data file 8). The decrease in β1-integrin RNA was
confirmed at the protein level by performing a fluorescence-
activated cell sorting analysis on intact cells with an antibody
that recognizes active β1-integrin (see Additional data file 9).
Integrin engagement is therefore likely to be decreased in
sFRP1-expressing MDA-MB-231 cells, which in turn is likely to
influence their proliferation. On the one hand fibronectin has
been shown to stimulate proliferation of cancer cells, and this
was associated with increased cyclin D1 and decreased
p21Cip1 levels [44]. Moreover, we have previously shown that
siRNA-mediated knockdown of β1-integrin in MDA-MB-231
cells increases p21Cip1 expression and leads to a proliferative
decrease [13]. We propose that integrin engagement would
be more strongly affected in vivo since not only the receptor
but also many of its extracellular matrix binding partners are
decreased in vivo.
In summary, the results presented here show that sFRP1-
mediated blockade of WNT signaling in MDA-MB-231 breast
cancer cells has an impact on the in vitro proliferation and
motility of the cancer cells. The in vivo effects of WNT pathway
blockade were even more dramatic since we observed a
strong decrease in the mammary tumor-forming potential and
an impairment of lung metastases. In summary, blockade of the
WNT-FZ interaction using sFRP1 has a strong effect on breast
tumor growth.
Conclusions
The results presented in this paper showing that sFRP1-medi-
ated WNT pathway blockade strongly blocks the in vivo tumor
forming potential of MDA-MB-231 breast cancer cells suggest
that interference with WNT signaling at the ligand-receptor
level may be a valid therapeutic approach in breast cancer.
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